Does routine multiplex mutational profiling of melanomas enable enrollment in genotype-driven therapeutic trials?
We present development of a simple mutational profiling screen for clinically relevant mutations in melanoma. Adoption of this genetically-informed approach to the treatment of melanoma has already had an impact on clinical trial enrollment and prioritization of therapy for patients with the disease.
SCO was offered through an outreach program rather than through in-clinic referrals. The study used a nonrandomized trial comparison group.